Phase 1 Brain Cancer Trial, Recruiting NCT06624371 Sponsor: Emory University Condition: Brain Cancer
Back to Brain Cancer

Phase 1 Brain Cancer Trial, Recruiting

NCT06624371
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Group 1 (Newly diagnosed patients):

  • You have been newly diagnosed with a specific type of childhood brain tumor (pediatric high-grade glioma, diffuse midline glioma, or diffuse intrinsic pontine glioma), confirmed by biopsy or MRI scan
  • You weigh more than 10 kg (about 22 lbs)
  • You are well enough to carry out at least some daily activities (as measured by a standard medical scale)
  • If you have seizures, they have been stable — meaning no seizures for at least 7 days and no need for new or stronger seizure medicines
  • Your liver, kidneys, and blood counts (including red blood cells, white blood cells, and platelets) are within acceptable ranges

Group 2 (Relapsed, progressive, or post-radiation patients):

  • Your brain tumor (high-grade glioma, diffuse midline glioma, diffuse intrinsic pontine glioma, or medulloblastoma) has returned or progressed, OR you have finished standard radiation and have not yet had progression
  • You are between 2 and 25 years old
  • You weigh more than 10 kg (about 22 lbs)
  • You have previously received standard treatments such as surgery, radiation, and/or chemotherapy
  • You have recovered from the side effects of your previous treatments
  • You have not previously taken the study drug atovaquone
  • Your seizures, if any, have been stable for at least 7 days with no need for new or stronger seizure medicines
  • Your liver, kidneys, and blood counts are within acceptable ranges
  • Patients with cancer that has spread to other parts of the body may be eligible for Group 2

Who may not be able to join:

  • You have a serious ongoing illness unrelated to your cancer (confirm with trial site)
  • You have had an allergic reaction to atovaquone or a very similar medication
  • Your tumor has spread to other parts of the body (Group 1 only — this is allowed in Group 2)
  • You have uncontrolled seizures, or your seizure medicines recently needed to be increased or changed
  • You have not yet fully recovered from the effects of a recent surgery
  • You are pregnant or breastfeeding; girls who have started their period must take a pregnancy test before joining
  • You are able to become pregnant or father a child and are not willing to use effective birth control during treatment and for 3 months after treatment ends
  • (Group 2 only) You have not waited long enough after your last cancer treatment — specific waiting periods apply depending on the type of treatment you received (confirm exact timeframes with trial site)
  • (Group 2 only) You have had a stem cell transplant less than 12 weeks ago
  • (Group 1 only) You have received any anti-cancer treatment other than radiation therapy
  • You have had significant bleeding inside your tumor

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Tobey MacDonald, MD, Emory University

Phone: 404-727-1447

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
28 March 2025
Est. completion
1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Drug Limiting toxicities (DLT) in Stratum 1; Drug Limiting toxicities (DLT) in Stratum 2

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov